ORMP - Oramed Pharmaceuticals Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ORMP

ORAMED PHARMACEUTICALS INC.

NASDAQ

$4.55

▲ UP 1.34% (0.06)

KEY STATISTICS

Market Cap$186.21 M

52w High$5.47

52w Low$2.09

Dividend Yield6.79%

FrequencySpecial

P/E2.36

Volume104.12K

Shares Out.40.93M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Nadav Kidron

COMPENSATION 2026

Salary$619,529

Stock Awards$3,709,269

Incentive Plan Pay$0

All Other Comp.$65,927

Total$4,774,460

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 1, 2007

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2013-01-23	Reverse	1:12
2004-06-14	Forward	33:10

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

22.78%

HOLDERS

TOP 8 OF 88 · RANKED BY POSITION SIZE

Bml Capital Management, LLC

3.2M sh

$9.03M

Mercer Global Advisors Inc /Adv

Boothbay Fund Management, LLC

845.4K sh

$2.23M

Marxe Austin W & Greenhouse David M

790.0K sh

$6.37M

Morgan Jess S & Co Inc

PRICE

$4.55 ▲ UP 1.34% (+$0.06)

OVERLAYS

About Oramed Pharmaceuticals Inc.

https://www.oramed.com ↗

Oramed Pharmaceuticals develops oral peptide-based treatments for diabetes, including insulin and GLP-1 capsules, with products in Phase I and II trials, aiming to revolutionize drug delivery.

INDUSTRY

Biotechnology

A PRODUCT ORAMED PHARMACEUTICALS INC. IS KNOWN FOR

ORMD-0801

ORMD-0801 is an oral insulin capsule for type 2 diabetes and NASH, with plans to restart Phase 3 trials targeting responsive patients after a 2023 setback, representing Oramed's main candidate for future commercialization.

COMPETITORS

COMPETITOR

Oramed Pharmaceuticals in 2025

SENTIMENT: + POSITIVE

EARNINGS · NOVEMBER 17, 2025

Oramed Pharmaceuticals Announces a $65 Million Net Income for the Third Quarter of 2025, a Significant Turnaround from the Previous Year's Loss

Oramed Pharmaceuticals reported a significant financial turnaround in its third quarter of 2025, posting a net income of $65.0 million compared to a net loss of $6.1 million for the same period in the prior year. This substantial increase was largely driven by the full repayment of a $100 million strategic investment from Scilex Holding Company and unrealized gains from its holdings in Alpha Tau Medical Ltd. The announcement also highlighted a 42% growth in the company's total assets year-over-year.

PARTNERSHIP · FEBRUARY 2025 · ANNOUNCED

Oramed Spins Off Core Oral Drug Delivery Technology into a New Joint Venture, OraTech Pharmaceuticals

Oramed entered into definitive agreements to spin off its proprietary Protein Oral Delivery (POD™) technology, including its oral insulin candidate ORMD-0801, into a new joint venture, OraTech Pharmaceuticals Inc., with Hefei Tianhui Biotech Co., Ltd. (HTIT). This move was intended to accelerate the development and commercialization of its core assets by combining Oramed's technology with HTIT's manufacturing capabilities.

Latest News

DEFENSE WORLD · OCT 4, 2026

Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB)

Generate Biomedicines (NASDAQ: GENB - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Profitability This table compares Generate Biomedicines and

READ ARTICLE